Immuno-oncology
Conference Coverage
Pembrolizumab improves 5-year OS in advanced NSCLC
CHICAGO – In a phase 1b trial of pembrolizumab, the 5-year OS rate was 23.2% in treatment-naive patients and 15.5% in previously treated patients...
Conference Coverage
Pembro as good as chemo for gastric cancers with less toxicity
CHICAGO – Pembrolizumab is now at least an alternative to chemotherapy, if not preferred, in many of these patients...
Conference Coverage
Low intensity bridging may be best path to CAR T in adult ALL
CHICAGO – Researchers examined the use of high- and low-intensity chemotherapy bridging for patients waiting for treatment with a CD19-directed...
Conference Coverage
Pembro with or without chemo superior to EXTREME for advanced HNSCC
CHICAGO – Pembrolizumab with and without chemotherapy proved superior for overall survival vs. the EXTREME regimen...
From the Journals
Novel anti-PD-1 antibody can be given subcutaneously
“Subcutaneous administration of an anti-PD-1 antibody in patients with advanced solid tumors appears to be feasible,” the investigators wrote.
From the Journals
Do some EGFR mutation subtypes benefit from immune checkpoint blockade?
One common EGFR tyrosine kinase inhibitor–sensitizing allele may be associated with similar benefit versus EGFR wild-type lung tumors, analysis...
Feature
CMS proposes payment increase for administering CAR T in the hospital
The CMS would raise the new technology add-on payment to hospitals for administration of CAR T-cell therapies from $186,500 to $242,450.
Conference Coverage
Myc signaling, monocytes predict NSCLC response to second-line entinostat + pembro
ATLANTA – Investigators have identified factors associated with response to combination entinostat and pembrolizumab among NSCLC patients who...
Conference Coverage
SRA737 + anti–PD-L1 therapy and low-dose gemcitabine shows early promise for SCLC
ATLANTA – Preclinical data suggest a role for SRA737 plus anti–PD-L1 therapy and low-dose gemcitabine in SCLC.
Conference Coverage
High pCR rate in HPV+ HNSCC with nivolumab/SBRT
ATLANTA – Nine of 10 patients in a phase 1/1b trial had pathologic complete responses to neoadjuvant nivolumab and radiation.
Conference Coverage
MYSTIC trial: bTMB correlates with tTMB, predicts survival in mNSCLC
ATLANTA – Blood TMB predicts survival benefit in mNSCLC patients treated with first-line durvalumab plus tremelimumab versus chemo, according to...